Ozempic-style drugs now in trials for heart failure, addiction and even aging

maccus.fr

95 points by randycupertino a day ago


AnthonBerg - 12 hours ago

It's interesting with GLP-1 agonists that they all curb inflammation and redox stress.

–All of heart failure, addiction, and aging certainly have inflammation and redox stress as substrate.

It's interesting that GLP-1 agonists all have pulmonary effects. There's GLP-1 receptors in the lung.

(the lung is somewhat relevant in redox stress / burden / balance

as well as neuroendocrine metabolism. the lung is a metabolic organ. it metabolizes serotonin. serotonin has… many roles, anciently repurposed for a ton of things.)

It's usually the case that anything that, say, curbs addiction? will curb inflammation and redox stress, and have pulmonary effects. Exercise, for one. Psychological safety. Healthier eating. 5-HT2A agonists. NMDA antagonists. And… GLP-1 agonists.

spooky old-man-oracle voice: everything is pulmonaaaaryyyy

potamic - 11 hours ago

Does GLP-1 help someone who eats because of boredom? My ADHD riddled brain seeks constant stimulation, so when there's nothing to do it turns to food even though there's no hunger or cravings. If I'm occupied with something, I can easily skip food and go on an extended fast, hunger suppression has never been a problem. But it's hard to stay occupied all the time, would GLP-1 help in such a case?

deskamess - 18 hours ago

For those who may have tried other variants... is there a big difference between Ozempic/Wegovy/Mounjaro? My doctor prescribed WeGovy but my insurance does not cover it - my spouses does. However Mounjaro is covered by both insurances. Is it worth (effectiveness) switching to Mounjaro? I heard it is a 'double agonist' - what exactly does that mean?

I am also reading up on things called triple agonist but its not readily available in Canada. Web sites with a lot of discussion about peptides and titrating which seems a little difficult.

gorfian_robot - 3 hours ago

if you want to hear endocrinologists talk with researchers and other qualified professionals about this space, I highly recommend this podcast.

https://docswholift.com/

recents topics:

The Truth About BPC-157 & Peptides

Retatrutide & Beyond: Eli Lilly Exec on Next-Gen GLP-1s

Retatrutide Phase 3 Results: What the Data Actually Means

arjie - 20 hours ago

These drugs are a godsend for so many (me included, on retatrutide) but especially for those of us here in America - legal environment broad enough to get them, relatively wealthy enough to afford them, and notably fat enough to benefit from them. The diffusion of this technology through the US might well increase American lifespan in a notable way.

Now all we need is an easy pill that makes you hate opioids.

gib444 - 20 hours ago

It totally solved my food addiction. It flipped it like a switch - I knew what most people are like, where food isn't a thought every 15 minutes. What a glorious time. So much free head space

It is now firmly back, after ~6 months off the drug (due to cost) :/

I've managed to keep off the lost weight, through a lot of willpower, but winter will be a struggle I can tell.

perching_aix - 19 hours ago

If a molecule can downregulate (downmodulate?) cravings so effectively, could there be a molecule that does the opposite?

This is basically about as far as I feel like entertaining conspiracy theories. I think it's a fairly grounded one, compared to most.

Not claiming that a molecule or a class of such molecules (or a perfect storm of unrelated molecules acting indirectly) is behind the obesity epidemic, or that there's explicit malicious intention involved, just that it does make me wonder.

bitwize - 4 hours ago

[dead]